Merck's New HIV Prevention Pill: Low-Cost Generics in Africa and India, but Latin America Access Uncertain

In a move aimed at ensuring broad access to its new HIV prevention pill, Merck has allowed companies in Africa and India to manufacture inexpensive generic versions of the drug. These generics are expected to cost as little as $5 per person per year, a significant step forward in the fight against HIV in regions with the highest prevalence.

However, while populations in Africa and India will benefit from this low-cost option, the situation in Latin America remains unclear. Merck has not yet announced similar licensing agreements for that region, raising concerns that many people in need of prophylaxis may be left without access. The new pill is considered a breakthrough because it is highly effective and requires less frequent dosing than traditional prevention methods, making its availability critical in the global health context.

Experts note that while the generic licensing move is welcome, more efforts are needed to ensure the drug reaches Latin American countries where HIV rates remain high. Merck representatives say they are working on solutions, but no specific dates or agreements have been announced yet.